BioPharmSignal logoBioPharmSignal

Biotech News

iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens

iSpecimen (ISPC)iSpecimenCompany update

Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer...

Related news

ISPCiSpecimen2023-10-26 07:30 EST

iSpecimen Expands Proprietary Provider Network to Help Advance Infectious Disease Research

ISPCiSpecimen2023-09-13 07:30 EST

iSpecimen Expands Provider Network to Enhance Support for Women's Health Research

View all latest news

iSpecimen

iSpecimen is a healthcare data and biospecimen marketplace company that connects researchers with human biospecimens and related services. Its role is to support research and translational work rather than develop therapies.

Recent company news

ISPCiSpecimen2025-01-16 16:01 EST

iSpecimen Secures Suppliers for COVID-style hMPV Outbreak

ISPCiSpecimen2024-12-20 08:30 EST

iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens

ISPCiSpecimen2024-12-13 07:30 EST

iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers

ISPCiSpecimen2024-12-12 17:11 EST

iSpecimen Appoints Robert Lim as CEO and Director

ISPCiSpecimen2024-11-08 07:30 EST

iSpecimen Named Top Competitor in $4.4 Billion USD Market

Stock data

Close
2.20 USD
Market cap
4.41M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States